Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Idiopathic Pulmonary Fibrosis
NCT00162760Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in idiopathic pulmonary fibrosis (IPF), sponsored by Johns Hopkins University. Primary endpoint: Safety, Feasibility, and Efficacy of Thalidomide at 1 year. Started Oct 2003; status: completed.
02
Drugs
thalidomide
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00162760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162760.